期刊
ADVANCED HEALTHCARE MATERIALS
卷 10, 期 10, 页码 -出版社
WILEY
DOI: 10.1002/adhm.202002207
关键词
catalase; engineered probiotics; radiosensitizers; tumor hypoxia microenvironments; tumor‐ targeting
资金
- Improvement Project for Theranostic ability on Difficulty Miscellaneous disease (Tumor) of Zhongnan Hospital of Wuhan University [ZLYNXM202008]
- National Natural Science Foundation of China [82073168]
- China Postdoctoral Science Foundation [2019M662517]
This study demonstrates the use of genetically engineered probiotic E. coli bacteria to alleviate intratumoral hypoxia and enhance tumor radiosensitivity by promoting O-2 evolution and ROS generation in response to X-ray irradiation, leading to significant inhibition of tumor growth. The findings suggest a promising approach to improve the efficacy of tumor radiotherapy and highlight the importance of future research in the field of probiotic medicine.
Owing to their ability to rapidly proliferate in specific niches and their amenability to genetic manipulation, bacteria are frequently studied as potential diagnostic or therapeutic bioagents in a range of pathological contexts. A sustained oxygen supply within solid tumors is essential in order to achieve positive radiotherapy (RT) outcomes, as these intratumoral oxygen levels are necessary to facilitate RT-induced reactive oxygen species (ROS) generation. In this study, a genetically engineered variant of the tumor-targeting probiotic E. coli Nissle 1917 bacteria that secret catalase is utilized to alleviate intratumoral hypoxia and to thereby enhance tumor radiosensitivity. These engineered bacteria are able to facilitate robust O-2 evolution and consequent ROS generation in response to X-ray irradiation both in vitro and in vivo, significantly inhibiting tumor growth. Overall, the study highlights a novel and practical approach to enhance the efficacy of tumor RT, underscoring the value of future research in the field of probiotic medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据